keyword
MENU ▼
Read by QxMD icon Read
search

Iron iv ferritin

keyword
https://www.readbyqxmd.com/read/28128726/the-safety-of-achieved-iron-stores-and-their-effect-on-iv-iron-and-esa-use-post-hoc-results-from-a-randomized-trial-of-ferric-citrate-as-a-phosphate-binder-in-dialysis%C3%A2
#1
Kausik Umanath, Barbara Greco, Diana I Jalal, Molly McFadden, Mohammed Sika, Mark J Koury, Robert Niecestro, Lawrence G Hunsicker, Tom Greene, Julia B Lewis, Jamie P Dwyer
Iron stores assuring optimal efficacy/safety for erythropoiesis are unknown in the dialysis population. Using multicenter trial data, we related safety profiles, erythropoiesis-stimulating agent (ESA), and intravenous iron dosing to achieved iron stores in 441 subjects randomized 2 : 1 to ferric citrate or active control as their phosphate binder over 52 weeks. Intravenous iron was given at each site's discretion if ferritin ≤ 1,000 ng/mL and transferrin saturation ≤ 30%. Multivariable time-dependent Cox regression jointly related the primary safety outcome (composite of cardiac, infection, gastrointestinal, and hepatobiliary serious adverse events) to moving averages of ferritin and transferrin saturation over the preceding 90 days with covariate adjustment...
January 27, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28095881/renal-function-in-patients-with-non-dialysis-chronic-kidney-disease-receiving-intravenous-ferric-carboxymaltose-an-analysis-of-the-randomized-find-ckd-trial
#2
Iain C Macdougall, Andreas H Bock, Fernando Carrera, Kai-Uwe Eckardt, Carlo Gaillard, David Van Wyck, Yvonne Meier, Sylvain Larroque, Simon D Roger
BACKGROUND: Preclinical studies demonstrate renal proximal tubular injury after administration of some intravenous iron preparations but clinical data on renal effects of intravenous iron are sparse. METHODS: FIND-CKD was a 56-week, randomized, open-label, multicenter study in which patients with non-dialysis dependent chronic kidney disease (ND-CKD), anemia and iron deficiency without erythropoiesis-stimulating agent therapy received intravenous ferric carboxymaltose (FCM), targeting either higher (400-600 μg/L) or lower (100-200 μg/L) ferritin values, or oral iron...
January 17, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28092401/randomized-clinical-trial-of-preoperative-oral-versus-intravenous-iron-in-anaemic-patients-with-colorectal-cancer
#3
B D Keeler, J A Simpson, O Ng, H Padmanabhan, M J Brookes, A G Acheson
BACKGROUND: Treatment of preoperative anaemia is recommended as part of patient blood management, aiming to minimize perioperative allogeneic red blood cell transfusion. No clear evidence exists outlining which treatment modality should be used in patients with colorectal cancer. The study aimed to compare the efficacy of preoperative intravenous and oral iron in reducing blood transfusion use in anaemic patients undergoing elective colorectal cancer surgery. METHODS: Anaemic patients with non-metastatic colorectal adenocarcinoma were recruited at least 2 weeks before surgery and randomized to receive oral (ferrous sulphate) or intravenous (ferric carboxymaltose) iron...
February 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28039585/iron-therapy-in-patients-with-heart-failure-and-iron-deficiency-review-of-iron-preparations-for-practitioners
#4
REVIEW
Marcin Drozd, Ewa A Jankowska, Waldemar Banasiak, Piotr Ponikowski
In patients with heart failure (HF), iron deficiency (ID) correlates with decreased exercise capacity and poor health-related quality of life, and predicts worse outcomes. Both absolute (depleted iron stores) and functional (where iron is unavailable for dedicated tissues) ID can be easily evaluated in patients with HF using standard laboratory tests (assessment of serum ferritin and transferrin saturation). Intravenous iron therapy in iron-deficient patients with HF and reduced ejection fraction has been shown to alleviate HF symptoms and improve exercise capacity and quality of life...
December 30, 2016: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/27994861/comparison-of-intravenous-low-molecular-weight-iron-dextran-and-intravenous-iron-sucrose-for-the-correction-of-anaemia-in-pre-dialysis-chronic-kidney-disease-patients-a-randomized-single-centre-study-in-nigeria
#5
Bala Waziri, Monica Mabayoje, Babawale Bello
BACKGROUND: Intravenous low molecular weight iron dextran and iron sucrose have been used for correction of iron deficiency for many years and have been shown to improve anaemia in chronic kidney disease (CKD). However, there is a paucity of head to head comparisons of these parenteral iron preparations. Such comparative efficacy data would be of particular interest in resource-limited African countries, where the majority of CKD patients are unable to afford erythropoiesis-stimulating agents...
December 2016: Clinical Kidney Journal
https://www.readbyqxmd.com/read/27932449/oral-iron-treatment-response-and-predictors-in-anaemic-adolescents-and-adults-with-ibd-a-prospective-controlled-open-label-trial
#6
David S Rampton, James R Goodhand, Neerav M Joshi, Abu-Bakarr Karim, Yasmine Koodun, Farah M Barakat, Lucia Macken, Douglas G Ward, Tariq H Iqbal, Jenny Epstein, John M Fell, Ian R Sanderson
BACKGROUND: Because of previous concerns about the efficacy and safety of oral iron for treating iron deficiency anaemia in inflammatory bowel disease [IBD], particularly in young people, we compared the effects of ferrous sulphate on haemoglobin response, disease activity and psychometric scores in adolescents and adults with IBD. We also assessed the relation of baseline serum hepcidin to haemoglobin response. METHODS: We undertook a prospective, open-label, 6-week non-inferiority trial of the effects of ferrous sulphate 200 mg twice daily on haemoglobin, iron status, hepcidin, disease activity (Harvey-Bradshaw Index, Simple Colitis Clinical Activity Index, C-reactive protein [CRP]), faecal calprotectin and psychometric scores in 45 adolescents [age 13-18 years] and 43 adults [>18 years]...
December 7, 2016: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/27873493/decitabine-as-a-first-line-treatment-for-older-adults-newly-diagnosed-with-acute-myeloid-leukemia
#7
Hyunsung Park, Haerim Chung, Jungyeon Lee, Jieun Jang, Yundeok Kim, Soo Jeong Kim, Jin Seok Kim, Yoo Hong Min, June Won Cheong
PURPOSE: Decitabine, a DNA hypomethylating agent, was recently approved for use in Korea for older adults with acute myeloid leukemia (AML) who are not candidates for standard chemotherapy. This study aimed to evaluate the role of decitabine as a first-line treatment for older adults with AML. MATERIALS AND METHODS: Twenty-four patients with AML who received at least one course of decitabine (20 mg/m²/d intravenously for 5 days every 4 weeks) as a first-line therapy at Severance Hospital were evaluated retrospectively...
January 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/27863761/iron-deficiency-in-cancer-patients
#8
Flávio Augusto Naoum
Anemia is a frequent complication in cancer patients, both at diagnosis and during treatment, with a multifactorial etiology in most cases. Iron deficiency is among the most common causes of anemia in this setting and can develop in nearly half of patients with solid tumors and hematologic malignancies. Surprisingly, this fact is usually neglected by the attending physician in a way that proper and prompt investigation of the iron status is either not performed or postponed. In cancer patients, functional iron deficiency is the predominant mechanism, in which iron availability is reduced due to disease or the therapy-related inflammatory process...
October 2016: Revista Brasileira de Hematologia e Hemoterapia
https://www.readbyqxmd.com/read/27852236/effects-of-intravenous-iron-on-fibroblast-growth-factor-23-fgf23-in-haemodialysis-patients-a-randomized-controlled-trial
#9
Matthew A Roberts, Louis Huang, Darren Lee, Robert MacGinley, Stefanie M A Troster, Annette B Kent, Sukhvinder S Bansal, Iain C Macdougall, Lawrence P McMahon
BACKGROUND: Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron used. METHODS: Prevalent, stable haemodialysis patients requiring protocol-based intravenous iron therapy were randomized to a single 200 mg dose of either ferric carboxymaltose (FCM) or iron sucrose (IS)...
November 16, 2016: BMC Nephrology
https://www.readbyqxmd.com/read/27793204/high-dose-intravenously-administered-iron-versus-orally-administered-iron-in-blood-donors-with-iron-deficiency-study-protocol-for-a-randomised-controlled-trial
#10
Susanne Macher, Camilla Drexler, Ines Lindenau, Nazanin Sareban, Peter Schlenke, Karin Amrein
BACKGROUND: About 2-3 % of the population participates in blood donation programmes. Each whole blood donation or ten apheresis donations cause a loss of 200-250 mg of iron. As a result, one of the most common risks of regular blood donors is iron deficiency. Although this has been known for decades, in most countries, iron status is currently not assessed or treated in this population. Premenopausal women are particularly affected, as they have lower iron reserves and higher daily requirements...
October 28, 2016: Trials
https://www.readbyqxmd.com/read/27774269/rationale-and-design-of-a-pilot-randomized-controlled-trial-to-assess-the-role-of-intravenous-ferric-carboxymaltose-in-asian-patients-with-heart-failure-practice-asia-hf
#11
Tee Joo Yeo, Poh Shuan Daniel Yeo, Farid Abdul Hadi, Timothy Cushway, Kim Yee Lee, Bee Choo Tai, Carolyn S P Lam
AIMS: Iron deficiency (ID) is highly prevalent in patients with heart failure (HF) worldwide regardless of haemoglobin levels. Results from therapeutic trials of intermittently dosed intravenous (i.v.) iron are promising in the ambulatory Caucasian population with HF with reduced left ventricular ejection fraction, although evidence is scarce in Asia. The Pilot Randomized Controlled Trial to Assess the Role of Intravenous Ferric Carboxymaltose in Asian Patients with Heart Failure aims to assess the effect of single-dose i...
June 2016: ESC Heart Failure
https://www.readbyqxmd.com/read/27692637/a-review-of-ferric-pyrophosphate-citrate-triferic-use-in-hemodialysis-patients
#12
Tyler Albright, Akram Al-Makki, Rabih Kalakeche, Brian Shepler
PURPOSE: The objective of this short review is to evaluate the efficacy of ferric pyrophosphate citrate and to determine its place in therapy based on the current published literature. METHODS: A literature search was conducted and pared down to yield 4 placebo controlled Phase II and III clinically relevant trials. FINDINGS: Ferric pyrophosphate citrate is a new intradialytic iron supplementation product that has been found to reduce the dose of erythropoiesis-stimulating agents and intravenous iron supplementation and to increase serum ferritin concentrations...
October 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27689830/rgd-targeting-of-human-ferritin-iron-oxide-nanoparticles-enhances-in-vivo-mri-of-vascular-inflammation-and-angiogenesis-in-experimental-carotid-disease-and-abdominal-aortic-aneurysm
#13
Toshiro Kitagawa, Hisanori Kosuge, Masaki Uchida, Yasunori Iida, Ronald L Dalman, Trevor Douglas, Michael V McConnell
PURPOSE: To evaluate Arg-Gly-Asp (RGD)-conjugated human ferritin (HFn) iron oxide nanoparticles for in vivo magnetic resonance imaging (MRI) of vascular inflammation and angiogenesis in experimental carotid disease and abdominal aortic aneurysm (AAA). MATERIALS AND METHODS: HFn was genetically engineered to express the RGD peptide and Fe3 O4 nanoparticles were chemically synthesized inside the engineered HFn (RGD-HFn). Macrophage-rich left carotid lesions were induced by ligation in FVB mice made hyperlipidemic and diabetic (n = 14), with the contralateral right carotid serving as control...
September 30, 2016: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/27619554/plasma-vitamin-c-levels-in-esrd-patients-and-occurrence-of-hypochromic-erythrocytes
#14
Eric Seibert, Anja Richter, Martin K Kuhlmann, Suxin Wang, Nathan W Levin, Peter Kotanko, Garry J Handelman
Introduction The achievement of erythropoiesis in hemodialysis (HD) patients is typically managed with erythropoiesis-stimulating-agents (ESA's) and intravenous iron (IV-iron). Using this treatment strategy, HD patients frequently show an elevated fraction of red blood cells (RBC) with hemoglobin (Hb) content per cell that is below the normal range, called hypochromic RBC. The low Hb content per RBC is the result of the clinical challenge of providing sufficient iron content to the bone marrow during erythropoiesis...
September 12, 2016: Hemodialysis International
https://www.readbyqxmd.com/read/27577248/-iron-deficiency-fatigue-and-restless-legs-syndrome
#15
Bettina Wurzinger, Peter König
Iron deficiency without anaemia is a widespread health problem that often remains undetected. In this context, neurological and psychopathological problems like fatigue and poor concentration are a major issue, but also in Restless-Legs-Syndrome (RLS) iron deficiency is a key element.The exact pathogenesis is often unknown, however, it is known that iron is involved in several very important metabolic processes in the human body. In particular when it comes to fatigue and RLS, it's assumed that reduced activity of tyrosine hydroxylase - a central iron-dependent element of dopamine synthesis - can lead to deficiencies...
October 2016: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27576956/pediatric-crohn-s-disease-iron-deficiency-anemia-and-intravenous-iron-treatment-a-follow-up-study
#16
Sara Valério de Azevedo, Catarina Maltez, Ana Isabel Lopes
BACKGROUND AND AIMS: Increasing evidence in adults demonstrates efficacy and safety of IV iron in inflammatory Bowel disease (IBD) associated iron deficiency anemia; however, evidence in pediatric patients is yet scarce and no previous study has included a long follow-up. This study aimed to evaluate safety and efficacy of IV iron (primary end point), and the need of re-treatment (secondary end point), in this setting. METHODS: Prospective recruitment (40 months); PCDAI determined before and after treatment; anemia defined according to WHO criteria; IV iron treatment included iron sucrose and ferric carboxymaltose...
January 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27570088/intravenous-ferric-carboxymaltose-versus-standard-care-in-the-management-of-postoperative-anaemia-a-prospective-open-label-randomised-controlled-trial
#17
Alhossain A Khalafallah, Carl Yan, Raghad Al-Badri, Ella Robinson, Brooke E Kirkby, Emily Ingram, Zara Gray, Vinod Khelgi, Iain K Robertson, Brian P Kirkby
BACKGROUND: Despite increasing efforts in perioperative management, postoperative iron deficiency anaemia persists, and few data are available about the management of this condition. In this study, we aimed to determine whether giving postoperative intravenous iron (in the form of ferric carboxymaltose) improved iron stores, haemoglobin concentrations, and outcomes following surgery. METHODS: We did a prospective, open-label, randomised, controlled study of patients at two centres (a general hospital and a private health-care centre) in Tasmania, Australia, undergoing elective surgery with functional iron deficiency anaemia (haemoglobin 70-120 g/L and ferritin ≤100 μg/L or iron saturation ≤20%), measured at day 1 postoperatively...
September 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27546308/mode-of-oral-iron-administration-and-the-amount-of-iron-habitually-consumed-do-not-affect-iron-absorption-systemic-iron-utilisation-or-zinc-absorption-in-iron-sufficient-infants-a-randomised-trial
#18
Ewa A Szymlek-Gay, Magnus Domellöf, Olle Hernell, Richard F Hurrell, Torbjörn Lind, Bo Lönnerdal, Christophe Zeder, Ines M Egli
Different metabolic pathways of supplemental and fortification Fe, or inhibition of Zn absorption by Fe, may explain adverse effects of supplemental Fe in Fe-sufficient infants. We determined whether the mode of oral Fe administration or the amount habitually consumed affects Fe absorption and systemic Fe utilisation in infants, and assessed the effects of these interventions on Zn absorption, Fe and Zn status, and growth. Fe-sufficient 6-month-old infants (n 72) were randomly assigned to receive 6·6 mg Fe/d from a high-Fe formula, 1·3 mg Fe/d from a low-Fe formula or 6·6 mg Fe/d from Fe drops and a formula with no added Fe for 45 d...
September 2016: British Journal of Nutrition
https://www.readbyqxmd.com/read/27542823/is-there-any-role-of-intravenous-iron-for-the-treatment-of-anemia-in-cancer
#19
Cengiz Gemici, Ozlem Yetmen, Gokhan Yaprak, Sevgi Ozden, Huseyin Tepetam, Hazan Ozyurt, Alpaslan Mayadagli
BACKGROUND: Anemia is a major cause of morbidity in patients with cancer resulting in poor physical performance, prognosis and therapy outcome. The aim of this study is to assess the efficacy of intravenous (iv) iron administration for the correction of anemia, for the prevention of exacerbation of anemia, for decreasing blood transfusion rates, and for the survival of cancer patients. METHODS: Patients with different solid tumor diagnosis who received iv iron during their cancer treatment were evaluated retrospectively...
August 20, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27540710/correction-of-iron-deficiency-anemia-with-intravenous-iron-sucrose-in-children-with-inflammatory-bowel-disease
#20
Istvan Danko, Marcy Weidkamp
OBJECTIVES: Iron deficiency anemia (IDA) is common in children with inflammatory bowel disease (IBD) affecting their cognitive development and school performance. Oral iron supplementation has serious limitations including poor adherence and iron malabsorption related to chronic inflammation. Our objective was to evaluate the feasibility of periodic intravenous (IV) iron treatments for correction of IDA in children with IBD. METHODS: This prospective study was conducted in 24 children with IBD treated with infliximab (IFX)...
November 2016: Journal of Pediatric Gastroenterology and Nutrition
keyword
keyword
98629
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"